Worldwide Locations
BD Worldwide > GeneOhm
GENEOHM

News


[bullet] First Partner Assay on the BD MAX™ System Launches in Europe »
[bullet] BD and Lab21 Collaborate to Develop New Oncology Assays on the BD MAX™ Platform  »
[bullet] New Molecular Assay Allows Healthcare Facilities to Simplify Active Surveillance Testing for Deadly Superbug  »
[bullet] New, Fully Automated BD MAX™ MRSA Assay Rapidly Identifies Patients Colonized with Deadly Superbug  »
[bullet] BD Diagnostics and Biodiversity Collaborate to Develop Portfolio of Assays on the BD MAX™ System »
[bullet] BD and Lab21 Collaborate to Develop Aspergillus Assay for New BD MAX™ Molecular Testing System  »
[bullet] BD Launches BD MAX™ System in U.S. to Empower Laboratories and Clinicians to Respond to Emerging Diseases »
[bullet] BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System  »
[bullet] BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians »
[bullet] BD Diagnostics and Lonza Collaborate to Commercialize the Lonza microCompass™ Molecular Assays on the BD MAX™ System »
[bullet] BD Receives CLIA "Moderate Complexity" Status for the BD MAX™ GBS Assay »
[bullet] BD Announces First FDA-Cleared Assay on the BD MAX™ System to Detect Group B Streptococcus  »
[bullet] BD Completes Acquisition of HandyLab, Inc. »
[bullet] BD Adds Surveillance Capability to Infectious Disease Portfolio »
[bullet] BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections »
[bullet] BD Receives CE Mark Approval for Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures »
Unless otherwise noted, BD, BD logo and all other trademarks are property of Becton Dickinson and Company. © 2013 BD